Difamilast
Sponsors
Acrotech Biopharma Inc.
Conditions
Atopic Dermatitis
Phase 3
A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
CompletedNCT05571943
Start: 2022-09-15End: 2024-07-31Updated: 2024-08-09
This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)
CompletedNCT05608343
Start: 2022-10-01End: 2023-10-27Updated: 2024-08-15